A multinational trial of prasugrel for sickle cell vaso-occlusive events

New England Journal of Medicine

Volumn 374, Issue 7, 2016, Pages 625-635

  Heeney, Matthew M ^a   Hoppe, Carolyn C ^b   Abboud, Miguel R ^c   Inusa, Baba ^d,e   Kanter, Julie ^h   Ogutu, Bernhards ⁱ   Brown, Patricia B ^l   Heath, Lori E ^l   Jakubowski, Joseph A ^l   Zhou, Chunmei ^l   Zamoryakhin, Dmitry ^f   Agbenyega, Tsiri ^m   Colombatti, Raffaella ^o   Hassab, Hoda M ^p   Nduba, Videlis N ^k   Oyieko, Janet N ^j   Robitaille, Nancy ^q   Segbefia, Catherine I ⁿ   Rees, David C ^g  

^a Dana Farber Boston Children's Cancer and Blood Disorders Center   (United States)

^b CHILDREN S HOSPITAL OAKLAND   (United States)

^c AMERICAN UNIVERSITY OF BEIRUT   (Lebanon)

^d EVELINA LONDON CHILDREN S HOSPITAL   (United Kingdom)

^e GUY'S AND ST THOMAS' NHS FOUNDATION TRUST   (United Kingdom)

^f DAIICHI SANKYO CO   (Japan)

^g KING S COLLEGE HOSPITAL   (United Kingdom)

^h MEDICAL UNIVERSITY OF SOUTH CAROLINA   (United States)

ⁱ US Army Medical Research Unit Kenya   (United States)

^j Kenya Medical Research Institute Walter Reed Project   (United States)

^k KENYA MEDICAL RESEARCH INSTITUTE   (Kenya)

^l ELI LILLY   (United States)

^m KWAME NKRUMAH UNIVERSITY OF SCIENCE AND TECHNOLOGY   (Ghana)

ⁿ KORLE BU TEACHING HOSPITAL   (Ghana)

^o UNIVERSITY HOSPITAL OF PADOVA   (Italy)

^p ALEXANDRIA UNIVERSITY   (Egypt)

^q UNIVERSITY OF MONTREAL   (Canada)

more..

Author keywords

[No Author keywords available]

Indexed keywords

ANALGESIC AGENT; CLOPIDOGREL; HYDROXYUREA; KETOROLAC; OPIATE; PLACEBO; PRASUGREL; ANTITHROMBOCYTIC AGENT;

ACUTE CHEST SYNDROME; ADOLESCENT; ADULT; AFRICA; ARTICLE; ASIA; BLEEDING; BRAIN ARTERY ANEURYSM; BRAIN HEMORRHAGE; CAUSE OF DEATH; CHILD; CONTROLLED STUDY; DOUBLE BLIND PROCEDURE; DRUG EFFICACY; DRUG FATALITY; DRUG SAFETY; EUROPE; FACES PAIN SCALE; FEMALE; FEVER; FOLLOW UP; HOSPITALIZATION; HUMAN; MAJOR CLINICAL STUDY; MALE; MORTALITY; PAIN; PAIN ASSESSMENT; PAIN INTENSITY; PHASE 3 CLINICAL TRIAL; PRESCHOOL CHILD; PRIORITY JOURNAL; RANDOMIZED CONTROLLED TRIAL; RESPIRATORY TRACT DISEASE; SCHOOL CHILD; SICKLE CELL ANEMIA; SICKLE CELL CRISIS; THORAX RADIOGRAPHY; TREATMENT DURATION; TREATMENT WITHDRAWAL; WESTERN HEMISPHERE; ANEMIA, SICKLE CELL; CHEMICALLY INDUCED; CLINICAL TRIAL; COMPLICATION; MULTICENTER STUDY; ORAL DRUG ADMINISTRATION; PERIPHERAL VASCULAR DISEASES;

ACUTE CHEST SYNDROME; ADMINISTRATION, ORAL; ADOLESCENT; ANEMIA, SICKLE CELL; CHILD; CHILD, PRESCHOOL; DOUBLE-BLIND METHOD; FEMALE; HEMORRHAGE; HUMANS; MALE; PAIN; PERIPHERAL VASCULAR DISEASES; PLATELET AGGREGATION INHIBITORS; PRASUGREL HYDROCHLORIDE;

EID: 84959019378     PISSN: 00284793     EISSN: 15334406     Source Type: Journal    
DOI: 10.1056/NEJMoa1512021     Document Type: Article

References (34)

1. Platt OS, Brambilla DJ, Rosse WF, et al. Mortality in sickle cell disease-life expectancy and risk factors for early death. N Engl J Med 1994; 330: 1639-44.
2. Maikler VE, Broome ME, Bailey P, Lea G. Childrens' and adolescents' use of diaries for sickle cell pain. J Soc Pediatr Nurs 2001;6:161-9.
3. Smith WR, Penberthy LT, Bovbjerg VE, et al. Daily assessment of pain in adults with sickle cell disease. Ann Intern Med 2008;148:94-101.
4. Frenette PS, Atweh GF. Sickle cell disease: old discoveries, new concepts, and future promise. J Clin Invest 2007; 117: 850-8.
5. Wang WC, Ware RE, Miller ST, et al. Hydroxycarbamide in very young children with sickle-cell anaemia: a multicentre, randomised, controlled trial (BABY HUG). Lancet 2011;377:1663-72.
6. Archer N, Galacteros F, Brugnara C. 2015 Clinical trials update in sickle cell anemia. Am J Hematol 2015; 90: 934-50.
7. Ataga KI, Key NS. Hypercoagulability in sickle cell disease: new approaches to an old problem. Hematology Am Soc He-matol Educ Program 2007: 91-6.
8. Wun T, Paglieroni T, Tablin F, Wel-born J, Nelson K, Cheung A. Platelet activation and platelet-erythrocyte aggregates in patients with sickle cell anemia. J Lab Clin Med 1997; 129: 507-16.
9. Tomer A. Platelet activation as a marker for in vivo prothrombotic activity: detection by flow cytometry. J Biol Regul Homeost Agents 2004;18:172-7.
10. Lee SP, Ataga KI, Orringer EP, Phillips DR, Parise LV. Biologically active CD40 ligand is elevated in sickle cell anemia: potential role for platelet-mediated inflammation. Arterioscler Thromb Vasc Biol 2006;26:1626-31.
11. Jakubowski JA, Winters KJ, Naganu-ma H, Wallentin L. Prasugrel: a novel thi-enopyridine antiplatelet agent-a review of preclinical and clinical studies and the mechanistic basis for its distinct anti-platelet profile. Cardiovasc Drug Rev 2007; 25: 357-74.
12. Beurling-Harbury C, Schade SG. Platelet activation during pain crisis in sickle cell anemia patients. Am J Hematol 1989; 31: 237-41.
13. Wun T, Paglieroni T, Rangaswami A, et al. Platelet activation in patients with sickle cell disease. Br J Haematol 1998; 100:741-9.
14. Osamo NO, Photiades DP, Famodu AA. Therapeutic effect of aspirin in sickle cell anaemia. Acta Haematol 1981; 66: 102-7.
15. Cabannes R, Lonsdorfer J, Castaigne JP, Ondo A, Plassard A, Zohoun I. Clinical and biological double-blind-study of ticlop-idine in preventive treatment of sickle-cell disease crises. Agents Actions Suppl 1984;15:199-212.
16. Niitsu Y, Jakubowski JA, Sugidachi A, Asai F. Pharmacology of CS-747 (prasug-rel, LY640315), a novel, potent antiplatelet agent with in vivo P2Y12 receptor antagonist activity. Semin Thromb Hemost 2005; 31:184-94.
17. Jakubowski JA, Zhou C, Small DS, et al. A phase 1 study of prasugrel in patients with sickle cell disease: pharmaco-kinetics and effects on ex vivo platelet reactivity. Br J Clin Pharmacol 2013; 75: 1433-44.
18. Wun T, Soulieres D, Frelinger AL, et al. A double-blind, randomized, multi-center phase 2 study of prasugrel versus placebo in adult patients with sickle cell disease. J Hematol Oncol 2013; 6: 17.
19. Styles L, Heiselman D, Heath LE, et al. Prasugrel in children with sickle cell disease: pharmacokinetic and pharmaco-dynamic data from an open-label, adaptive-design, dose-ranging study. J Pediatr Hematol Oncol 2015;37:1-9.
20. Hoppe CC, Styles L, Heath LE, et al. Design of the DOVE (Determining Effects of Platelet Inhibition on Vaso-Occlusive Events) Trial: a global phase 3 double-blind, randomized, placebo-controlled, multicenter study of the efficacy and safety of prasugrel in pediatric patients with sickle cell anemia utilizing a dose titra-tion strategy. Pediatr Blood Cancer 2015 September 24 (Epub ahead of print).
21. Yawn BP, Buchanan GR, Afenyi-An-nan AN, et al. Management of sickle cell disease: summary of the 2014 evidence-based report by expert panel members. JAMA 2014;312:1033-48.
22. Pocock SJ, Simon R. Sequential treatment assignment with balancing for prognostic factors in the controlled clinical trial. Biometrics 1975;31:103-15.
23. Li JS, Yow E, Berezny KY, et al. Dosing of clopidogrel for platelet inhibition in infants and young children: primary results of the Platelet Inhibition in Children On cLOpidogrel (PICOLO) trial. Circulation 2008;117:553-9.
24. Wessel DL, Berger F, Li JS, et al. Clop-idogrel in infants with systemic-to-pulmonary-artery shunts. N Engl J Med 2013; 368:2377-84.
25. Hicks CL, von Baeyer CL, Spafford PA, van Korlaar I, Goodenough B. The Faces Pain Scale-Revised: toward a common metric in pediatric pain measurement. Pain 2001;93:173-83.
26. Berde CB, Walco GA, Krane EJ, et al. Pediatric analgesic clinical trial designs, measures, and extrapolation: report of an FDA scientific workshop. Pediatrics 2012; 129:354-64.
27. McGrath PJ, Walco GA, Turk DC, et al. Core outcome domains and measures for pediatric acute and chronic/recurrent pain clinical trials: PedIMMPACT recommendations. J Pain 2008; 9: 771-83.
28. Fuggle P, Shand PA, Gill LJ, Davies SC. Pain, quality of life, and coping in sickle cell disease. Arch Dis Child 1996; 75: 199-203.
29. Gil KM, Porter L, Ready J, Workman E, Sedway J, Anthony KK. Pain in children and adolescents with sickle cell disease: an analysis of daily pain diaries. Child Health Care 2000;29:225-41.
30. Jacob E, Beyer JE, Miaskowski C, Save-dra M, Treadwell M, Styles L. Are there phases to the vaso-occlusive painful episode in sickle cell disease? J Pain Symptom Manage 2005; 29: 392-400.
31. Ballas SK, Gupta K, Adams-Graves P. Sickle cell pain: a critical reappraisal. Blood 2012;120:3647-56.
32. Hebbel RP. Ischemia-reperfusion injury in sickle cell anemia: relationship to acute chest syndrome, endothelial dysfunction, arterial vasculopathy, and inflammatory pain. In: Vichinsky EP, ed. Emerging therapies targeting the patho-physiology of sickle cell disease. Philadelphia: Saunders, 2014:181-98.
33. Platt OS, Thorington BD, Brambilla DJ, et al. Pain in sickle cell disease-rates and risk factors. N Engl J Med 1991; 325:11-6.
34. Tantry US, Bonello L, Aradi D, et al. Consensus and update on the definition of on-treatment platelet reactivity to ade-nosine diphosphate associated with ischemia and bleeding. J Am Coll Cardiol 2013; 62:2261-73.